Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$618.46 USD

618.46
1,324,097

-5.75 (-0.92%)

Updated Sep 11, 2024 04:00 PM ET

After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Tivity Health's (TVTY) Shares Fall Despite Q3 Earnings Beat

Tivity Health (TVTY) reports solid revenue growth in its Nutrition arm in the third quarter due to strength in Nutrisystem brand DTC.

HMS Holdings (HMSY) Climbs 7.4% Post In-Line Q3 Earnings

HMS Holdings (HMSY) witnessed revenue growth in COB and PI segments in the third quarter.

Owens & Minor's (OMI) Shares Fall Despite Q3 Earnings Beat

Owens & Minor (OMI) reports solid revenue growth in its Global Products arm in the third quarter due to strength in PPE sales.

AMN Healthcare (AMN) Loses 9.4% Despite Q3 Earnings Beat

AMN Healthcare (AMN) gained from Technology and Workforce Solutions segment in the third quarter.

Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)

Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.

Hill-Rom (HRC) Q4 Earnings, Revenues Top Estimates, Fall Y/Y

In Q3, Hill-Rom's (HRC) bed orders and backlog in the United States accelerates with sequential recovery in Patient Support Systems arm.

Glaukos (GKOS) Gains 11.8% Despite Reporting Loss in Q3

Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

Myriad Genetics' (MYGN) Q1 Earnings & Revenues Top Estimates

Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.

Luminex (LMNX) Declines 6.6% as Q3 Earnings Miss Estimates

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.

National Vision (EYE) Q3 Earnings Top Estimates, Margins Up

National Vision (EYE) witnesses comparable growth on increased customer transaction in Q3.

Co-Diagnostics (CODX) to Post Q3 Earnings: What's in Store?

Co-Diagnostics' (CODX) third-quarter results are likely to reflect higher COVID-19 test sales.

Tandem Diabetes (TNDM) Q3 Earnings Miss, '20 Sales View Up

Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.

Nevro (NVRO) Rallies 1.3% Despite Delivering Loss in Q3

Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.

CVS Health (CVS) Q3 Earnings Top Estimates, 2020 View Up

CVS Health's (CVS) Q3 pharmacy claims processed rise attributable to strong net new business, partially offset by reduced new therapy prescriptions.

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Contracts

Zimmer Biomet (ZBH) registers stronger-than-expected recovery of elective procedures in the third quarter.

Phibro (PAHC) Q1 Earnings Surpass Estimates, Margins Up

Phibro's (PAHC) core Animal Health segment, along with strength in Nutritional Specialties and Vaccines, boosted Q1 performance despite pandemic-led business disruptions.

LHC Group (LHCG) Q3 Earnings and Revenues Beat Estimates

LHC Group's (LHCG) third-quarter results benefit from organic growth in home health as well hospice admissions.

Cardiovascular Systems' (CSII) Q1 Earnings Top Estimates

Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.

Inogen (INGN) Stock Loses 9.2% After Delivering Loss in Q3

Inogen (INGN) saw revenue decline within its Sales segment in Q3

PRA Health (PRAH) Gains 4.3% Following Q3 Earnings Beat

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the third quarter.

Becton Dickinson (BDX) Earnings Surpass Estimates in Q4

Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in the fiscal fourth quarter.

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates

DENTSPLY SIRONA (XRAY) rides high on the launch of the Axeos imaging system in the third quarter.

Haemonetics (HAE) Q2 Earnings Beat Estimates, Margins Down

Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.

Insulet (PODD) Q3 Earnings & Revenues Top Estimates, View Up

Insulet's (PODD) Q3 gross margin improvement can be primarily attributed to performance of the company's U.S. manufacturing and favorable revenue mix from the shift to higher volume